Evaluation and management of osteoporosis in liver disease

Clinics in Liver Disease

Volumn 9, Issue 4, 2005, Pages 747-766

  Hay, J Eileen ^a   Guichelaar, Maureen M J ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLESTYRAMINE; CORTICOSTEROID; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; ISOFLAVONE; LITHIUM; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

ALLOGRAFT; AUTOIMMUNE DISEASE; BODY MASS; BONE ATROPHY; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE REMODELING; CALCIUM DEFICIENCY; CHOLESTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; GENETIC REGULATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYDROXYLATION; HYPOGONADISM; HYPOTHYROIDISM; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MALABSORPTION; MECHANICAL STRESS; NUTRITION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT SELECTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SCORING SYSTEM; SCREENING; SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

BONE DENSITY; BONE DISEASES, METABOLIC; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 26044480987     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.07.003     Document Type: Review

References (123)

1. J.E. Hay Osteoporosis in liver diseases and after liver transplantation J Hepatol 38 2003 856 865
2. J.E. Hay Bone disease in cholestatic liver disease Gastroenterology 108 1995 276 283
3. P. Angulo, T.M. Teherneau, and A. Jorgensen Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression J Hepatol 29 1998 729 735
4. A. Monegal, M. Navasa, and N. Guanabens Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation Calcif Tissue Int 60 1997 148 154
5. M. Ninkovic, S.A. Love, and B. Tom High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation Calcif Tissue Int 69 2001 321 326
6. E.J. Carey, V. Balan, and W.K. Kremers Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem Liver Transpl 9 2003 1166 1173
7. C. Trautwein, M. Possienki, and H.J. Schlitt Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation Am J Gastroenterol 95 2000 2343 2351
8. T. Diamond, D. Stiel, and S. Posen Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 110 1989 430 436
9. A.J. Stellon, A. Davies, and J. Compston Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy Gastroenterol 89 1985 1078 1083
10. J.E. Compston Osteoporosis after liver transplantation Liver Transpl 9 2003 321 330
11. A. Stellon, A. Davies, and J. Compston Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy Gastroenterol 89 1985 1078 1083
12. M. Camisasca, A. Crosignani, and P.M. Battezzati Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis Hepatology 20 1994 633 637
13. K. Menon, P. Angulo, and S. Weston Bone disease in primary biliary cirrhosis: independent indicators and rate of progression J Hepatol 35 2001 316 323
14. N. Guanaens, A. Pares, and L. Caballeria Severity of cholestis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis J Hepatol 42 2005 573 577
15. M. Guichelaar, J. Hay, and B. Clark Pretransplant bone histomorphometric status of patients with end-stage cholestatic liver disease J Hepatol 32 2000 54
16. J. Heubi, B. Hollis, and B. Specker Bone disease in chronic childhood cholestasis. I. Vitamin D absorption and metabolism Hepatology 9 1989 258 264
17. J. Bucuvalas, W. Cutfield, and J. Horn Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease J Pediatr 117 1990 397 402
18. E. Argao, W. Balistreri, and B.W. Hollis Effect of orthotopic liver transplantation on bone mineral content and serum vitamin D metabolites in infants and children with chronic cholestasis Hepatology 20 1994 598 603
19. F. Gallego-Rojo, J. Bonzalez-Calvin, and M. Muñoz-Torres Bone mineral density, serum insulin-like growth factor I and bone turnover markers in viral cirrhosis Hepatology 28 1998 695 699
20. K. Masaki, S. Shiomi, and T. Kuroki Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver J Gastroenterol 33 1998 236 250
21. S. Feitelberg, S. Epstein, and F. Ismail Deranged bone mineral metabolism in chronic alcoholism Metabolism 36 1987 322 326
22. T. Diamond, D. Stiel, and S. Posen Osteoporosis in hemochromatosis: iron excess, gonadal deficiency or other factors? Ann Intern Med 110 1989 430 436
23. H.L. Bonkovsky, M. Hawkins, and K. Steinberg Prevalence and prediction of osteopenia in chronic liver disease Hepatology 12 1990 273 280
24. O. Crosbie, R. Freaney, and M.J. McKenna Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease Calcif Tissue Int 64 1999 295 300
25. S. Hussaini, B. Oldroyd, and S.P. Stewart Regional bone mineral density after orthotopic liver transplantation Eur J Gastroenterol Hepatol 11 1999 157 163
26. T. Diamond, D. Stiel, and M. Lunzer Osteoporosis and skeletal fractures in chronic liver disease Gut 31 1990 82 87
27. R.P. Sokhi, A. Anantharaju, and R. Kondaveeti Bone mineral density among cirrhotic patients awaiting liver transplantation Liver Transpl 10 2004 648 653
28. D. Dempster, and R. Lindsay Pathogenesis of osteoporosis Lancet 341 1993 797 805
29. S. Manolagas, and R. Jilka Bone marrow, cytokines, and bone remodeling N Engl J Med 332 1995 305 311
30. E. Eriksen, M. Kassem, and B. Langdahl Growth hormone, insulin-like growth factors and bone remodeling Eur J Clin Invest 26 1996 525 534
31. J. Compston, and R. Thompson Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis Lancet 309 8014 1997 721 724
32. A. Kehayoglou, C. Holdsworth, and J.E. Agnew Bone disease and calcium absorption in primary biliary cirrhosis Lancet 291 7545 1968 715 719
33. M. Kaplan, M. Goldberg, and D.E. Matloff Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis Gastroenterology 81 1981 681 685
34. R. Skinner, R. Long, and S. Sherlock 24-hydroxylation of vitamin D in primary biliary cirrhosis Lancet 309 8014 1997 720 721
35. M.M.J. Guichelaar, M. Malinchoc, and J. Sibonga Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry Hepatology 36 2002 895 903
36. H. Herlong, and R. Recker Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D Gastroenterol 83 1982 103 108
37. D. Matloff, M. Kaplan, and R.M. Neer Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment Gastroenterol 83 1982 97 102
38. T. Diamond, D. Stiel, and M. Lunzer Ethanol reduces bone formation and may cause osteoporosis Am J Med 86 1989 282 288
39. J. Jorge-Hernandez, C. Gonzalez-Reimers, and A. Torres-Ramirez Bone changes in alcoholic liver cirrhosis. A histomorphometrical analysis of 52 cases Dig Dis Sci 33 1988 1089 1095
40. S. Mobarhan, R. Russell, and R.R. Recker Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 24-hydroxyvitamin D, or supportive treatment Hepatology 4 1984 266 273
41. R. Jilka Cytokines, bone remodeling, and estrogen deficiency: a 1998 update Bone 23 1998 75 81
42. S. Pignata, B. Daniele, and M.G. Galati Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma Eur J Gastroenterol Hepatol 9 1997 283 285
43. H. Bell, N. Raknerud, and J.A. Falch Inappropriately low levels of gonadotrophins in amenorrheic women with alcoholic and non-alcoholic cirrhosis Eur J Endocrinol 132 1995 444 449
44. J. Iwamoto, T. Takeda, and Y. Sato Effects of vitamin K2 on osteoporosis Current Pharm Design 10 2004 2557 2576
45. S. Shiomi, S. Nishiguchi, and S. Kubo Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver AJG 97 2002 578 581
46. J. Dai, D. Lin, and J. Zhang Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice J Clin Invest 106 2000 887 895
47. B. Lalor, M. France, and D. Powell Bone and mineral metabolism and chronic alcohol abuse Q J Med 59 1986 497 511
48. S.H. Ralston Genetic control of susceptibility to osteoporosis J Clin Endocrinol Metab 87 2002 2460 2466
49. J. Springer, D. Cole, and L.A. Rubin Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis Gastroenterol 118 2000 145 151
50. A. Pares, N. Guanabens, and L. Alvarez Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis Hepatology 33 2001 554 560
51. J. Guardiola, X. Ziol, and J.M. Nolla Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation Ann Intern Med 131 1999 752 755
52. J. Hay Vitamin D receptor polymorphism and post-transplantation bone loss Liver Transpl 7 2001 68 72
53. J.D. Collier, M. Ninkovic, and J.E. Compston Guidelines on the management of osteoporosis associated with chronic liver disease Gut 50 Suppl 2002 s1 s9
54. M. Porayko, R. Wiesner, and J.E. Hay Bone disease in liver transplant recipients: incidence, timing and risk factors Transplant Proc 23 1991 1462 1465
55. J. Hay, and M. Guichelaar Bone mineral density in the first decade after liver transplantation Hepatology 32 2000 239A
56. R. Eastell, E. Dickson, and S.F. Hodgson Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis Hepatology 14 1991 296 300
57. J. Hay, K. Lindor, and R.H. Wiesner The metabolic bone disease of primary sclerosing cholangitis Hepatology 14 1991 257 261
58. A. Floreani Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC) Gut 50 2002 898 899
59. S. Ormarsdottir, O. Ljunggren, and H. Mallmin Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease J Hepatol 31 1999 84 90
60. J. Newton, R. Francis, and M. Prince Osteoporosis in primary biliary cirrhosis revisited Gut 49 2001 282 287
61. C. Janes, E. Dickson, and R. Okazaki Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice J Clin Invest 95 1995 2581 2586
62. Z. Ackerman, M. Weinreb, and G. Amir Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease Liver 22 2002 166 172
63. K. Tsuneoka, Y. Tameda, and K. Takase Osteodystrophy in patients with chronic hepatitis and liver cirrhosis J Gastroenterol 31 1996 669 678
64. W. Simonet, D. Lacey, and C.R. Dunstan Osteoportegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
65. S.W. van der Merwe, J.B. van den Bogaerde, and C. Goosen Hepatic osteodystrophy in rats results mainly from portasystemic shunting Gut 52 2003 580 585
66. R. Adler, and C. Rosen Glucocorticoids and osteoporosis Endocrinol Metab Clin North Am 23 1994 641 654
67. H.W. Vesper, L.M. Demers, and R. Eastell Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline Clin Chem 48 2002 220 235
68. N. Guanabens, A. Pares, and L. Alvarez Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis J Bone Miner Res 13 1998 731 738
69. M. Guichelaar, J.E. Hay, and M. Malinchoc Pretransplant bone histomorphometric status of patients with end-stage cholestatic liver disease J Hepatol 32 2000 54
70. R. Eastell, and H. Lambert Diet and healthy bones Calcif Tissue Int 70 2002 400 404
71. B.H. Arjmandi, D.A. Khalil, and B.J. Smith Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion J Clin Endocrinol Metab 88 2003 1048 1054
72. R. Prince, M. Smith, and I.M. Dick Prevention of postmenopausal osteoporosis N Engl J Med 325 1991 1189 1195
73. R. Heaney Calcium in the prevention and treatment of osteoporosis J Int Med 231 1992 169 180
74. I. Reid, R. Ames, and M.C. Evans Effect of calcium supplementation on bone loss in postmenopausal women N Engl J Med 328 1993 460 464
75. J. Crippin, R. Jorgensen, and E.R. Dickson Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment Am J Gastroenterol 89 1994 47 50
76. NIH consensus development panel on optimal calcium intake. Optimal calcium intake JAMA 272 1994 1942 1948
77. S. Shiomi, K. Masaki, and D. Habu Calcitriol for bone loss in patients with primary biliary cirrhosis J Gastroenterol 34 1999 241 245
78. S. Shiomi, K. Masaki, and D. Habu Calcitriol for bone disease in patients with cirrhosis of the liver J Gastroenterol Hepatol 14 1999 547 552
79. P.J. Meunier, P.D. Delmas, and R. Eastell Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines Clin Ther 21 1999 1025 1044
80. R. Marcus, M. Wong, and H. Heath III Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint Endocr Rev 23 2002 16 37
81. S. Epstein The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy Mayo Clin Proc 80 2005 379 388
82. H.D. Nelson, L.L. Humphrey, and P.M.A. Nygren Postmenopausal hormone replacement therapy: scientific review JAMA 288 2002 872 881
83. A. Cranney, G. Guyatt, and L. Griffith IX: summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 2002 570 578
84. Clinical synthesis panel on HRT. Hormone replacement therapy Lancet 354 1999 152 155
85. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
86. R. Olsson, L.A. Mattsson, and K. Obrant Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis Liver 19 1999 188 192
87. K.V.N. Menon, P. Angulo, and G.M. Boe Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis Am J Gastroenterol 98 2003 889 892
88. D. Clements, and J. Rhodes Hormone replacement therapy in chronic active hepatitis; a case report Gut 34 1993 1639 1640
89. E. Lufkin, H. Wahner, and W.M. O'Fallon Treatment of postmenopausal osteoporosis with transdermal estrogen Ann Intern Med 117 1992 1 9
90. S.P. Pereira, J. Donohue, and C. Moniz Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial Aliment Pharmacol Ther 19 2004 563 570
91. L. Fitzpatrick Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal woman Mayo Clin Proc 74 1999 601 607
92. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene JAMA 282 1999 637 645
93. C. Bagatell, and W. Bremner Androgens in men-uses and abuses N Engl J Med 334 1996 707 714
94. N. Watts, S. Harris, and H.K. Genant Intermittent cyclical etidronate treatment of postmenopausal osteoporosis N Engl J Med 323 1990 73 79
95. A. Cranney, G. Wells, and A. Willan Meta-analysis of alendronate for the treatment of postmenopausal women Endocr Rev 23 2002 508 516
96. S.A. Quandt, D.E. Thompson, and D.L. Schneider Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the fracture intervention trial Mayo Clin Proc 80 2005 343 349
97. J. Adachi, W. Bensen, and J. Brown Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis N Engl J Med 337 1997 382 387
98. K. Saag, R. Emkey, and T.J. Schnitzer Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 1998 292 299
99. H.G. Bone, D. Hosking, and J.P. Devogelaer Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 2004 1189 1199
100. S. Riemens, A. Oostdijk, and J.J. Van Doormall Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol Osteoporos Int 6 1996 213 218
101. N. Guanabens, A. Pares, and A. Monegal Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years Gastroenterology 113 1997 219 224
102. M. Valero, C. Loinaz, and L. Larrodera Calcitonin and bisphosphonates treatment in bone loss after liver transplantation Calcif Tissue Int 57 1995 15 19
103. N. Guanabens, A. Pares, and I. Ros Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis Am J Gastroenterol 98 2003 2268 2274
104. F. Wolfhagen, H. van Buuren, and J.W. den Ouden Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis J Hepatol 26 1997 325 330
105. I. Reid, J.P. Brown, and P. Burckhardt Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 2002 653 661
106. H. Reeves, R. Francis, and D.M. Manas Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation Liver Transpl Surg 4 1998 404 409
107. G. Mazzuoli, M. Passeri, and C. Gennari Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study Calcif Tissue Int 38 1986 3 8
108. Fatourechi V., Heath H. [editorial]. Salmon calcitonin in the treatment of postmenopausal osteoporosis. Ann Intern Med 1987;107:923-5
109. I. MacIntyre, M.I. Whitehead, and L.M. Banks Calcitonin for prevention of postmenopausal bone loss Lancet 331 8591 1998 900 901
110. K. Overgaard, M. Hansen, and S.B. Jensen Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study BMJ 305 1992 556 561
111. A. Cranney, P. Tugwell, and N. Zytaruk Meta-analysis of calcitonin for the treatment of postmenopausal women Endocr Rev 23 2002 540 551
112. A. Floreani, F. Zappala, and R. Naccarato A 3-year pilot study with 1,25-diydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis J Clin Gastroenterol 24 1997 239 244
113. B. Riggs, S. Hodgson, and W.M. O'Fallon Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis N Engl J Med 322 1990 802 809
114. N. Guanabens, A. Pares, and L. del Rio Sodium fluoride prevents bone loss in primary biliary cirrhosis J Hepatol 15 1992 345 349
115. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
116. A.B. Hodsman, D.A. Hanley, and M.P. Ettinger Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis J Clin Endocrinol Metab 88 2003 5212 5220
117. J.J. Body, G.A. Gaich, and W.H. Scheele A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 2002 4528 4535
118. D.M. Black, S.L. Greenspan, and K.E. Ensrud The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
119. J.S. Finkelstein, A.N. Hayes, and J.L. Hunzelman The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 2003 1215 1226
120. A. Verma, J.D. Maxwell, and L. Ang Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis Osteoporos Int 13 2002 677 682
121. K. Lindor, C. Janes, and J.S. Crippin Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 21 1995 389 392
122. A. Cemborain, I. Castilla-Cortazar, and M. Carcia Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment J Hepatol 28 1998 122 131
123. J.D. Wallace, W.J. Abbott-Johnson, and D.H.G. Crawford GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study J Clin Endocrinol Metab 87 2002 2751 2759